Anacetrapib + Placebo anacetrapib
Phase 3Active 0 watching 0 views this week📈 Rising
77
Development Stage
✓
Pre-clinical✓
Phase 1✓
Phase 24
Phase 35
ApprovedIndication / Disease
Atherosclerotic Cardiovascular Disease
Conditions
Atherosclerotic Cardiovascular Disease
Trial Timeline
Jun 1, 2011 → Jan 31, 2037
NCT ID
NCT01252953About Anacetrapib + Placebo anacetrapib
Anacetrapib + Placebo anacetrapib is a phase 3 stage product being developed by Merck for Atherosclerotic Cardiovascular Disease. The current trial status is active. This product is registered under clinical trial identifier NCT01252953. Target conditions include Atherosclerotic Cardiovascular Disease.
Hype Score Breakdown
Clinical
27
Activity
18
Company
10
Novelty
9
Community
10
Clinical Trials (1)
| NCT ID | Phase | Status |
|---|---|---|
| NCT01252953 | Phase 3 | Active |
Competing Products
20 competing products in Atherosclerotic Cardiovascular Disease